AANEM News Express

AANEM News Express

AANEM Urges FDA to Expedite Development of ALS Treatments

3/28/2013
 
AMA at ALS public hearing
American Medical Association representative testifies at the ALS public hearing.
 
The AANEM submitted comments to the U.S. Food and Drug Administration (FDA), supporting those of The ALS Association and the Muscular Dystrophy Association, urging the FDA to take action to help expedite the development and approval of new treatments for ALS. These comments were in response to the first ever ALS-specific public hearing held by the FDA on February 25, 2013. 
 
Key items addressed in the comments asked the FDA to:
  • Hold follow-up meetings of key stakeholders,
  • Refine preclinical development and clinical trial design in ALS,
  • Understand better the benefit-risk assessment in treatment in ALS patients, and
  • Accelerate review of devices that impact the quality and length of life in ALS patients.
Download the comments (PDF)

The AANEM will continue to work to support more research and improved quality of life for ALS patients.


View Related News Stories:

  Education


Recent AANEM News

Latest Anthology of Articles from the News Science Editorial Board Now Available

Science News: Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis

Muscle & Nerve Reveals Top 5 Downloaded Articles of 2019

Science News: Degree of Agreement between Electrodiagnostic Testing and Magnetic Resonance Imaging in the Evaluation of Brachial Plexopathy

AANEM Calls For Research in Neuromuscular/Electrodiagnostic Medicine





Advertisement

ABEM

Advertisement

TPP

Advertisement

Ultra EMG